隔离灌注治疗肝癌药物选择现状与展望  

Drug selection in isolated hepatic perfusion for nonresectable liver tumors: recent trends and perspectives

作　　者：叶华[1] 陆才德[1] 郑四鸣[1] 

机构地区：[1]宁波大学医学院附属李惠利医院肝胆胰外科,浙江省宁波市315040

出　　处：《世界华人消化杂志》2008年第23期2621-2625,共5页World Chinese Journal of Digestology

摘　　要：肝脏隔离灌注(isolated hepatic perfusion,IHP)是将肝脏血液循环和体循环完全隔离,用全身无法耐受的药物剂量对肝脏肿瘤进行灌注化疗的方法.近年临床研究肝脏隔离灌注化疗药物主要使用马法兰或马法兰联合肿瘤坏死因子(tumor nicrosis factor-α,TNF-α)及联合高温等,初步结果显示IHP较之传统疗法对不能切除的肝癌疗效有所提高.本文就目前肝脏隔离灌注中药物选择的现状及今后发展等进行综述.Isolated hepatic perfusion （IHP） involves a method of complete vascular isolation of the liver to take the advantage of directed intensive chemotherapy that has minimal systemic toxicity. Recent clinical studies mainly employed melphalan with or without tumor necrosis factor alpha （TNF-α）, or with hyperthermia in IHP. The results of these studies showed that higher response rates and survival rates could be achieved by IHP than by traditional therapeutics for non-resectable liver tumors. In this article, we discussed the current status, recent developments and future perspectives of drug selection in IHP.

关 键 词：肝脏隔离灌注 肝脏肿瘤 5-氟尿嘧啶 马法兰 肿瘤坏死因子 

分 类 号：R735.7[医药卫生—肿瘤]